LYEL(Lyell Immunopharma, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $10.65M | $84.68M | $130.00K | $61.00K | $36.00K |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$214.78M | −$187.06M | −$247.01M | −$358.75M | −$269.40M |
| 净利润 | −$250.22M | −$183.12M | −$234.63M | −$342.99M | −$274.45M |
| 经营现金流 | −$126.25M | −$169.56M | −$163.69M | −$162.39M | −$150.02M |
| 自由现金流 | −$191.75M | −$193.83M | −$166.38M | −$162.86M | −$150.80M |
| 摊薄每股收益 | $-36.80 | $-14.80 | $-18.70 | $-26.23 | $-16.06 |